Whole Genome Sequencing analysis platform v2

Description

NGC was established to realise the National Strategy for Personalised Medicine 2017–2020. It is intended to ensure governance and coordination of the strategy’s initiatives at the national level. The Danish efforts within Personalised Medicine are to focus on the patients. The vision of NGC is to create a foundation for the development of a more precise diagnosis, targeted treatment and strengthened research within the Danish healthcare system. The core mission of the NGC is to establish and operate a state-of-the-art and secure national infrastructure for personalised medicine in cooperation with the Regions and universities. To accomplish this, several patient groups with various diseases including cancer have been enrolled in a national effort to improve treatment through whole genome sequencing (WGS). WGS samples are sequenced at NGC’s sequencing facilities, followed by processing on NGC infrastructure. The whole genome sequencing analysis platform announced in this Tender (hereinafter referred to as “the solution”) will be used in the data processing part on NGC’s infrastructure. The users of the solution will be clinical academics from the Danish regional healthcare system, research scientists from Danish universities, and NGC’s bioinformaticians themselves. In the beginning we expect that only a few users will run on the platform. Gradually the number of users of the platform are expected to increase to a very rough estimate of around 10-20 different sites/groups in Denmark, with 2 – 4 users per site/group. We anticipate around a maximum of 30 concurrent users. These rough estimates are subject to change. The users will log into the NGC HPC infrastructure wherefrom they will access the solution, and analyse data within the HPC infrastructure. The solution will not have internet access. The contract is not divided into lots. The requirements for the contract are described in Appendix 1.